Sputnik Light Vaccine Description
Russia's Sputnik Light is the first component (recombinant human adenovirus 26 serotype (rAd26) of the Sputnik V vaccine. The Sputnik Light vaccine is based on a proven and well-studied platform of human adenoviral vectors, which cause the common cold and have been around for thousands of years, as demonstrated by the Russian Gamaleya Center during laboratory tests.
Adenoviruses, which are found in the respiratory tract and regularly cause acute respiratory infections, have become the most commonly used viruses to engineer vectors. Scientists from the Gamaleya Center have been working on adenoviral vector-based vaccines since the 1980s and now lead the world to develop these vaccines.
The effectiveness of Sputnik Light was found 79.4% based on the analysis of data from the 28th day after receiving immunization by citizens of the Russian Federation as part of the mass vaccination program in the period December 5, 2020 - April 15, 2021. The Sputnik Light vaccine elicits the development of virus-neutralizing antibodies in 91.67% of individuals on the 28th-day post-immunization. And the cellular immune response against the S Protein of SARS-CoV-2 develops in 100% of volunteers on the 10th day.
On May 6, 2021, the Ministry of Health of the Russian Federation, the National Research Center for Epidemiology and Microbiology, and the Russian Direct Investment Fund (RDIF) announced the single-component Sputnik Light vaccine registration.
The immunization of individuals with pre-existing immunity against SARS-CoV-2 with Sputnik Light can elicit the increase of antigen-specific IgG antibodies by more than 40x in 100% of subjects ten days after immunization. Sputnik Light international clinical trials included about 7,000 people from Moscow, Russia, Ghana, the United Arab Emirates, and other countries.
On May 24, 2021, the RDIF announced data from a study conducted by the Institute of Virology of the National University of Cordoba (Argentina) and the authorities of Cordoba, which confirmed 85.5% of individuals developed IgG antibodies to the SARS-CoV-2 coronavirus on the 14th day after receiving the first injection of Sputnik V.
The RDIF is Russia's sovereign wealth fund established in 2011. The Federal Government Budgetary Institution, "National Research Center for Epidemiology and Microbiology," is one of Russia’s oldest scientific research centers and celebrated its 100th anniversary in 1991.
Sputnik Light Vaccine Indication
Sputnik Light is indicated to build immunity to SARS-CoV-2, which causes COVID-19 disease. CNBC reported on May 6, 2021, the Sputnik Light vaccine developed by the Gamaleya Research Institute has an efficacy rate of 79.4%
Sputnik Light Vaccine Dosage
Sputnik Light is the first component (recombinant human adenovirus 26 serotype (rAd26) of the Sputnik V vaccine, which was Approved in August 2020.
Sputnik Light Adverse Events
As of June 2021, no serious adverse events were registered after vaccination with Sputnik Light. In addition, real-world vaccination data in Serbia on May 28, 2021, confirmed no serious vaccine-related adverse events.
Sputnik Light Vaccine Cost
The cost of the Sputnik Light vaccine globally could be less than $10, while it has simple storage requirements, at +2 +8, which provide for easy logistics.
Sputnik Light Vaccine Availability
As of June 16, 2021, the Sputnik Light vaccine was available in (11) countries: Russia, Venezuela, Angola, Bahrain, Nicaragua, Palestine, Mauritius, Argentina, Belarus, Republic of Congo, and Mongolia.
Sputnik Light Vaccine News
June 11, 2021 - The RDIF announced the approval of the single-dose Sputnik Light vaccine by the Ministry of Health of Mongolia.
June 7, 2021 - The Republic of Congo's Ministry of Health Approved the single-dose Sputnik Light vaccine.
June 4, 2021 - TASS reported foreign nationals employed in Russia would be offered the Sputnik Light vaccine, according to Russian Health Minister Mikhail Murashko.
June 3, 2021 - Reuters reported Belarus had registered the Sputnik Light vaccine against COVID-19 for use.
June 2, 2021 - The RDIF announced data from the Ministry of Health of the province of Buenos Aires, Argentina, which demonstrated the high efficiency of the Sputnik Light vaccine at the level of 78.6-83.7% when vaccinating the elderly. According to the analysis of data, more than 186 thousand people aged 60 to 79 years, more than 40 thousand of whom received an injection of the "Sputnik Light" vaccine during the mass vaccination of the population, the SARS-CoV-2 virus incidence in the period from 21 to 40 days after receiving one injection was only 0.446%. The incidence among the adult unvaccinated population for the same period was 2.74%.
June 2, 2021 – The Russian Direct Investment Fund announced the approval of the single-dose Sputnik Light vaccine by the Ministry of Health and Wellness of the Republic of Mauritius.
May 31, 2021 – The RDIF announced the approval of the Sputnik Light vaccine by the Ministry of Health of the State of Palestine.
May 31, 2021 - Reuters reported Dr. Reddy's Laboratories is in active discussions to bring the Sputnik Light vaccine into India.
May 24, 2021 - A study conducted by the Institute
of Virology of the National University of Cordoba located in Argentina and the authorities of Cordoba confirmed 14 days after receiving the first injection of Sputnik V, 85.5% of individuals developed SARS-CoV-2 coronavirus IgG antibodies.
May 20, 2021 - The Russian Direct Investment Fund announced the approval of the single-dose Sputnik Light vaccine by the Ministry of Health of the Republic of Nicaragua.
May 15, 2021 - The Bolivarian Republic of Venezuela authorized the Sputnik Light vaccine.
May 12, 2021 - The Republic of Angola registered the Sputnik Light vaccine.
May 12, 2021 - Reuters reported the South American country of Venezuela would soon receive the Sputnik Light vaccine.
May 6, 2021 - The effectiveness of the single-component vaccine "Sputnik Light" was 79.4% based on the analysis of data from the 28th day after receiving immunization by citizens of the Russian Federation as part of the mass vaccination program in the period December 5, 2020 - April 15, 2021. An efficacy rate of about 80% exceeds that of many vaccines requiring two shots.
Sputnik Light Vaccine Clinical Trials
Sputnik Light is undergoing several clinical trials.